

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Genscript Biotech Corporation**

**金斯瑞生物科技股份有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1548)**

### **POSITIVE PROFIT ALERT**

This announcement is made by the Company pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Inside Information Provisions under Part XIVA of the Securities and Future Ordinance.

The board of directors (the “**Board**”) of Genscript Biotech Corporation (the “**Company**”, together with its subsidiaries, collectively, the “**Group**”) wishes to inform the shareholders of the Company and potential investors that, based on the latest review of the unaudited management accounts of the Group for the year ended December 31, 2016 (the “**Management Accounts**”) and the information currently available to the Group, the Group is expected to record a significant increase in the net profit for the year ended December 31, 2016, as compared to the year ended December 31, 2015, mainly due to the increase of sales. The orders of life sciences research services and preclinical drug development services rose significantly, primarily benefiting from our continuous research and development activities which resulted in the launch of advanced and/or improved services and products and improvement in our production efficiency. Since the Company completed the acquisition of Jinan Nornoon Biological Engineering Co., Ltd\* (濟南諾能生物工程有限公同) in June 2016, both the number of customers and their purchase volume of industrial synthetic biology products increased, primarily due to the diversified product lines and enhanced marketing activities.

The information contained in this announcement is only based on a preliminary assessment by the Board with reference to the Management Accounts and the information currently available, which is subject to finalization and adjustments where necessary, and has not been reviewed or audited by the Company's auditors or audit committee. The Company is still in the process of finalizing the annual results of the Group for the year ended December 31, 2016. Financial information and other details of the Group will be disclosed in the annual results announcement of the Group for the year ended December 31, 2016.

Shareholders of the Company and potential investors are advised to read carefully the annual results announcement of the Company for the year ended December 31, 2016, which will be published before the end of March 2017 pursuant to the requirements of the Listing Rules.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Genscript Biotech Corporation**  
**Zhang Fangliang**  
*Chairman*

Hong Kong, February 8, 2017

*As at the date of this announcement, our executive Directors are Dr. ZHANG Fangliang, Ms. WANG Ye, and Mr. MENG Jiange; our non-executive Directors are Dr. WANG Luquan, Mr. HUANG Zuie-Chin, and Mr. PAN Yuexin; and our independent non-executive Directors are Mr. GUO Hongxin, Mr. DAI Zumian, and Ms. ZHANG Min.*

*\* For identification purposes only*